A Case of Pulmonary Adenocarcinoma Complicated with Systemic Sclerosis
-
- Takahashi Kei
- Department of Internal Medicine, Iwamizawa municipal General Hospital
-
- Takashina Taichi
- Department of Internal Medicine, Iwamizawa municipal General Hospital
-
- Watanabe Masahiro
- Department of Internal Medicine, Iwamizawa municipal General Hospital
-
- Kamimura Akira
- Department of Internal Medicine, Iwamizawa municipal General Hospital
-
- Ogura Shigeaki
- Department of Internal Medicine, Iwamizawa municipal General Hospital
Bibliographic Information
- Other Title
-
- 全身性強皮症を合併した肺腺癌に免疫チェックポイント阻害薬併用の化学療法が奏効し,骨転移巣への放射線照射を回避できた1例
Search this article
Abstract
<p>Background. There are few reports on the efficacy and safety of immune checkpoint inhibiter (ICI) in patients with autoimmune diseases. Irradiation for systemic sclerosis patients has been reported to cause late adverse events and is not a favorable indication. We herein report a case of pulmonary adenocarcinoma complicated with systemic sclerosis in which chemotherapy combined with an ICI was successful, allowing radiotherapy to be avoided. Case. A 67-year-old man had been diagnosed with systemic sclerosis at 55 years old and been under treatment at another hospital. He was referred to our hospital, when he has had a complaint of a back pain and was noted abnormalities on his CT scan. After a close examination, he was diagnosed with pulmonary adenocarcinoma that metastasized to the thoracic vertebrae. The metastasis in the vertebrae extended into the spinal canal, but the patient had systemic sclerosis, so irradiation carried a high risk. Because the tumor expressed high PD-L1, chemotherapy with an ICI was finally selected. Both the primary tumor and metastasis in the thoracic vertebrae were remarkably reduced without serious adverse events. Conclusion. ICI administration to systemic sclerosis patients may be a treatment option. However, cautious consideration is required, as this approach may increase the frequency of exacerbation of preexisting disease and immune-related adverse events.</p>
Journal
-
- Haigan
-
Haigan 63 (7), 953-958, 2023-12-20
The Japan Lung Cancer Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390017124024145536
-
- ISSN
- 13489992
- 03869628
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed